Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges

In oncology, an increasing number of targeted anticancer agents and immunotherapies are of biological origin. These biological drugs may trigger immune responses that lead to the formation of antidrug antibodies (ADAs). ADAs are directed against immunogenic parts of the drug and may affect efficacy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2016-10, Vol.21 (10), p.1260-1268
Hauptverfasser:	Brummelen, Emilie M.J., Ros, Willeke, Wolbink, Gertjan, Beijnen, Jos H., Schellens, Jan H.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies - analysis Antibodies - toxicity Antibodies, Monoclonal - immunology Antibody Formation Antidrug antibody Antineoplastic Agents - immunology Biological Products - immunology Biological Products - pharmacokinetics Biological Products - therapeutic use Cancer Clinical relevance Detection assays Efficacy Humans Immune Tolerance Immunogenicity Ipilimumab New Drug Development and Clinical Pharmacology Oncology Pharmacokinetics Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!